Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
BF.7: virus neutralization
BQ.1.1
COVID-19
SARS-CoV-2
XBB
convalescent plasma
Journal
The Journal of general virology
ISSN: 1465-2099
Titre abrégé: J Gen Virol
Pays: England
ID NLM: 0077340
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
15
5
2023
pubmed:
11
5
2023
entrez:
11
5
2023
Statut:
ppublish
Résumé
Recent 2022 SARS-CoV-2 Omicron variants, have acquired resistance to most neutralizing anti-Spike monoclonal antibodies authorized, and the BQ.1.* sublineages are notably resistant to all authorized monoclonal antibodies. Polyclonal antibodies from individuals both vaccinated and recently recovered from Omicron COVID-19 (VaxCCP) could retain new Omicron neutralizing activity. Here we reviewed BQ.1.* virus neutralization data from 920 individual patient samples from 43 separate cohorts defined by boosted vaccinations (Vax) with or without recent Omicron COVID-19, as well as infection without vaccination (CCP) to determine level of BQ.1.* neutralizing antibodies and percent of plasma samples with neutralizing activity. More than 90 % of the plasma samples from individuals in the recently (within 6 months) boosted VaxCCP study cohorts neutralized BQ.1.1, and BF.7 with 100 % neutralization of WA-1, BA.4/5, BA.4.6 and BA.2.75. The geometric mean of the geometric mean 50 % neutralizing titres (GM (GMT
Identifiants
pubmed: 37167085
doi: 10.1099/jgv.0.001854
pmc: PMC10336427
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Review
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI152078
Pays : United States
Organisme : NCATS NIH HHS
ID : U24 TR001609
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003098
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
EBioMedicine. 2023 Apr;90:104545
pubmed: 37002990
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
Cell. 2023 Jan 19;186(2):279-286.e8
pubmed: 36580913
bioRxiv. 2022 Oct 20;:
pubmed: 36299423
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Lancet Infect Dis. 2023 Jan;23(1):22-23
pubmed: 36410372
mBio. 2023 Apr 25;14(2):e0352322
pubmed: 36786604
Emerg Infect Dis. 2022 Mar;28(3):672-683
pubmed: 35202525
Nat Med. 2023 Feb;29(2):344-347
pubmed: 36473500
N Engl J Med. 2023 Feb 16;388(7):662-664
pubmed: 36652339
JAMA Netw Open. 2023 Jan 3;6(1):e2250647
pubmed: 36633846
Nature. 2023 Feb;614(7948):521-529
pubmed: 36535326
N Engl J Med. 2023 Mar 2;388(9):854-857
pubmed: 36734885
N Engl J Med. 2023 Jan 12;388(2):183-185
pubmed: 36546661
Nat Commun. 2022 Oct 29;13(1):6478
pubmed: 36309490
Nat Commun. 2023 Feb 14;14(1):824
pubmed: 36788246
Nat Commun. 2023 May 11;14(1):2671
pubmed: 37169744
Blood Adv. 2022 Jun 28;6(12):3678-3683
pubmed: 35443020
Clin Infect Dis. 2023 Jun 16;76(12):2077-2086
pubmed: 36809473
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625